Skip to main content
SpringerLink
Log in

Prevalence and Risk Factors Associated with Use of QT-Prolonging Drugs in Hospitalized Older People

  • Original Research Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Aims

The objective of this study was to evaluate the prevalence of the prescription of QT-prolonging drugs at hospital admission and discharge and the risk factors associated with their use in older people (aged 65 years and older).

Methods

Data were obtained from the REPOSI (REgistro POliterapie SIMI [Società Italiana di Medicina Interna]) registry, which enrolled 4035 patients in 2008 (n = 1332), 2010 (n = 1380), and 2012 (n = 1323). Multivariable logistic regression was performed to determine the risk factors independently associated with QT-prolonging drug use. QT-prolonging drugs were classified by the risk of Torsades de Pointes (TdP) (definite, possible, or conditional) according to the Arizona Center for Education and Research on Therapeutics (AzCERT) classification. Specific drug combinations were also assessed.

Results

Among 3906 patients prescribed at least one drug at admission, 2156 (55.2 %) were taking at least one QT-prolonging drug. Risk factors independently associated with the use of any QT-prolonging drugs were increasing age (odds ratio [OR] 1.02, 95 % CI 1.01–1.03), multimorbidity (OR 2.69, 95 % CI 2.33–3.10), hypokalemia (OR 2.79, 95 % CI 1.32–5.89), atrial fibrillation (OR 1.66, 95 % CI 1.40–1.98), and heart failure (OR 3.17, 95 % CI 2.49–4.05). Furosemide, alone or in combination, was the most prescribed drug. Amiodarone was the most prescribed drug with a definite risk of TdP. Both the absolute number of QT-prolonging drugs (2890 vs. 3549) and the number of patients treated with them (2456 vs. 2156) increased at discharge. Among 1808 patients not prescribed QT-prolonging drugs at admission, 35.8 % were prescribed them at discharge.

Conclusions

Despite their risk, QT-prolonging drugs are widely prescribed to hospitalized older persons. The curriculum for both practicing physicians and medical students should be strengthened to provide more education on the appropriate use of drugs in order to improve the management of hospitalized older people.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart. 2003;89(11):1363–72.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  2. CredibleMeds®. https://www.crediblemeds.org. Accessed 30 Jan 2015.

  3. Zhang Y, Post WS, Blasco-Colmenares E, Dalal D, Tomaselli GF, Guallar E. Electrocardiographic QT interval and mortality: a meta-analysis. Epidemiology. 2011;22(5):660–70.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Montanez A, Ruskin JN, Hebert PR, Lamas GA, Hennekens CH. Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population: a review and qualitative overview of the prospective cohort studies. Arch Intern Med. 2004;164(9):943–8.

    Article  PubMed  Google Scholar 

  5. European Medicines Agency (EMA). Domperidone-containing medicines. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Domperidone-containing_medicines/human_referral_prac_000021.jsp&mid=WC0b01ac05805c516f. Accessed 30 Jan 2015.

  6. Bardai A, Amin AS, Blom MT, Bezzina CR, Berdowski J, Langendijk PN, et al. Sudden cardiac arrest associated with use of a non-cardiac drug that reduces cardiac excitability: evidence from bench, bedside, and community. Eur Heart J. 2013;34(20):1506–16.

    Article  PubMed  CAS  Google Scholar 

  7. Straus SM, Bleumink GS, Dieleman JP, van der Lei J, ‘t Jong GW, Kingma JH, et al. Antipsychotics and the risk of sudden cardiac death. Arch Intern Med. 2004;164(12):1293–7.

    Article  PubMed  Google Scholar 

  8. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012;366(20):1881–90.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  9. Kazmierczak J, Peregud-Pogorzelska M, Rzeuski R. QT interval prolongation and torsades de pointes due to a coadministration of ciprofloxacin and azimilide in a patient with implantable cardioverter-defibrillator. Pacing Clin Electrophysiol. 2007;30(8):1043–6.

    Article  PubMed  Google Scholar 

  10. Keivanidou A, Arnaoutoglou C, Krommydas A, Papanikolaou G, Tsiptses K, Chrisopoulos C, et al. Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy. Cardiol J. 2009;16(2):172–4.

    PubMed  Google Scholar 

  11. Letsas KP, Sideris A, Kounas SP, Efremidis M, Korantzopoulos P, Kardaras F. Drug-induced QT interval prolongation after ciprofloxacin administration in a patient receiving olanzapine. Int J Cardiol. 2006;109(2):273–4.

    Article  PubMed  Google Scholar 

  12. Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F. QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone. Pacing Clin Electrophysiol. 2005;28(5):472–3.

    Article  PubMed  Google Scholar 

  13. Boyce MJ, Baisley KJ, Warrington SJ. Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo-controlled, double-blind, crossover study. Br J Clin Pharmacol. 2012;73(3):411–21.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  14. Burger CI, Clase CM, Gangji AS. Case report: drug interaction between tacrolimus and amiodarone with QT prolongation. Transplantation. 2010;89(9):1166–7.

    Article  PubMed  Google Scholar 

  15. Charbit B, Alvarez JC, Dasque E, Abe E, Demolis JL, Funck-Brentano C. Droperidol and ondansetron-induced QT interval prolongation: a clinical drug interaction study. Anesthesiology. 2008;109(2):206–12.

    Article  PubMed  CAS  Google Scholar 

  16. Slovacek L, Priester P, Petera J, Slanska I, Kopecky J. Tamoxifen/norfloxacin interaction leading to QT interval prolongation in a female patient with extracranial meningioma. Bratisl Lek Listy. 2011;112(6):353–4.

    PubMed  CAS  Google Scholar 

  17. Thomas AR, Chan LN, Bauman JL, Olopade CO. Prolongation of the QT interval related to cisapride–diltiazem interaction. Pharmacotherapy. 1998;18(2):381–5.

    PubMed  CAS  Google Scholar 

  18. Samarendra P, Kumari S, Evans SJ, Sacchi TJ, Navarro V. QT prolongation associated with azithromycin/amiodarone combination. Pacing Clin Electrophysiol. 2001;24(10):1572–4.

    Article  PubMed  CAS  Google Scholar 

  19. Marengoni A, Angleman S, Melis R, Mangialasche F, Karp A, Garmen A, et al. Aging with multi-morbidity: a systematic review of the literature. Ageing Res Rev. 2011;10:430–9.

    Article  PubMed  Google Scholar 

  20. Bernabei R, Caputi A, Di Cioccio L, Fini M, Gallo PF, Marchionni N, et al. Need for redesigning pharmacologic research in older individuals. A position statement of the Geriatric Working Group of the Agenzia Italiana del Farmaco (AIFA). J Gerontol A Biol Sci Med Sci. 2011;66:66–7.

    Article  PubMed  Google Scholar 

  21. Nobili A, Licata G, Salerno F, Pasina L, Tettamanti M, Franchi C, SIMI Investigators, et al. Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study. Eur J Clin Pharmacol. 2011;67:507–19.

    Article  PubMed  Google Scholar 

  22. Pasina L, Djade CD, Nobili A, Tettamanti M, Franchi C, Salerno F, et al. Drug-drug interactions in a cohort of hospitalized elderly patients. Pharmacoepidemiol Drug Saf. 2013;22:1054–60.

    PubMed  Google Scholar 

  23. Nachimuthu S, Assar MD, Schussler JM. Drug-induced QT interval prolongation: mechanisms and clinical management. Ther Adv Drug Saf. 2012;3(5):241–53.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Mannucci PM, Nobili A, REPOSI Investigators. Multimorbidity and polypharmacy in the elderly: lessons from REPOSI. Intern Emerg Med. 2014;9(7):723–34.

    Article  PubMed  Google Scholar 

  25. Shah S, Vanclay F, Cooper B. Improving the sensitivity of the Barthel Index for stroke rehabilitation. J Clin Epidemiol. 1989;42:703–9.

    Article  PubMed  CAS  Google Scholar 

  26. Miller MD, Towers A. Manual of guidelines for scoring the Cumulative Illness Rating Scale for Geriatrics (CIRS-G). Pittsburg: University of Pittsburgh; 1991.

    Google Scholar 

  27. Curtis LH, Østbye T, Sendersky V, Hutchison S, Allen LaPointe NM, Al-Khatib SM, et al. Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med. 2003;114(2):135–41.

    Article  PubMed  CAS  Google Scholar 

  28. Onder G, Bonassi S, Abbatecola AM, Folino-Gallo P, Lapi F, Marchionni N, Geriatrics Working Group of the Italian Medicines Agency, et al. High prevalence of poor quality drug prescribing in older individuals: a nationwide report from the Italian Medicines Agency (AIFA). J Gerontol A Biol Sci Med Sci. 2014;69(4):430–7.

    Article  PubMed  Google Scholar 

  29. Tay KY, Ewald MB, Bourgeois FT. Use of QT-prolonging medications in US emergency departments, 1995–2009. Pharmacoepidemiol Drug Saf. 2014;23(1):9–17.

    Article  PubMed  CAS  Google Scholar 

  30. Pasina L, Nobili A, Tettamanti M, Salerno F, Corrao S, Marengoni A, et al. Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly. Eur J Intern Med. 2011;22(2):205–10.

    Article  PubMed  CAS  Google Scholar 

  31. Pasquier M, Pantet O, Hugli O, Pruvot E, Buclin T, Waeber G, et al. Prevalence and determinants of QT interval prolongation in medical inpatients. Intern Med J. 2012;42(8):933–40.

    Article  PubMed  CAS  Google Scholar 

  32. Vandael E, Marynissen T, Reyntens J, Spriet I, Vandenberghe J, Willems R, et al. Frequency of use of QT-interval prolonging drugs in psychiatry in Belgium. Int J Clin Pharm. 2014;36(4):757–65.

    Article  PubMed  Google Scholar 

Download references

Author contributions

Study concept and design: Carlotta Franchi, Ilaria Ardoino. Acquisition, analysis, or interpretation of data: Carlotta Franchi, Ilaria Ardoino. Drafting of the manuscript: Carlotta Franchi, Ilaria Ardoino. Critical revision of the manuscript for important intellectual content: all authors. Statistical analysis: Ilaria Ardoino. Study supervision: Carlotta Franchi, Pier Mannuccio Mannucci, Alessandro Nobili.

Author information

Author notes

    Authors and Affiliations

    1. Department of Neuroscience, IRCCS-Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy

      C. Franchi, A. Nobili, L. Pasina & M. Tettamanti

    2. Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy

      I. Ardoino, E. M. Biganzoli & M. Marcucci

    3. Department of Pathophysiology and Transplantation, Fondazione IRCCS Cà Granda–Ospedale Maggiore Policlinico, Milan, Italy

      R. Rossio

    4. Department of Clinical and Experimental Science, University of Brescia, Brescia, Italy

      A. Marengoni

    5. Geriatrics Unit, Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico, Milan, Italy

      M. Marcucci

    6. Dipartimento Biomedico di Medicina Interna e Specialistica, University of Palermo, Palermo, Italy

      S. Corrao

    7. A. Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico, Milan, Italy

      P. M. Mannucci

    Authors
    1. C. Franchi
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. I. Ardoino
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. R. Rossio
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. A. Nobili
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. E. M. Biganzoli
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. A. Marengoni
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. M. Marcucci
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. L. Pasina
      View author publications

      You can also search for this author in PubMed Google Scholar

    9. M. Tettamanti
      View author publications

      You can also search for this author in PubMed Google Scholar

    10. S. Corrao
      View author publications

      You can also search for this author in PubMed Google Scholar

    11. P. M. Mannucci
      View author publications

      You can also search for this author in PubMed Google Scholar

    Consortia

    The REPOSI Investigators

    Corresponding author

    Correspondence to C. Franchi.

    Ethics declarations

    Funding

    No funding was received for the conduct of this study or preparation of this manuscript.

    Conflict of interest

    C Franchi, I Ardoino, R Rossio, A Nobili, E M. Biganzoli, A Marengoni, M Marcucci, L Pasina, M Tettamanti, S Corrao, P M Mannucci declare that they have no conflict of interest.

    Additional information

    C. Franchi and I. Ardoino contributed equally to this work.

    REPOSI denotes the REgistro POliterapie SIMI (Società Italiana di Medicina Interna); the full list of contributors is available online as Electronic Supplementary Material.

    Electronic supplementary material

    Below is the link to the electronic supplementary material.

    Supplementary material 1 (PDF 96 kb)

    Supplementary material 2 (PDF 49 kb)

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Franchi, C., Ardoino, I., Rossio, R. et al. Prevalence and Risk Factors Associated with Use of QT-Prolonging Drugs in Hospitalized Older People. Drugs Aging 33, 53–61 (2016). https://doi.org/10.1007/s40266-015-0337-y

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s40266-015-0337-y

    Keywords

    Search

    Navigation